Semax: Identity, Evidence, and Documentation

Semax is cataloged here as a synthetic acth(4–10)-derived heptapeptide. Semax is a seven-amino-acid synthetic analog derived from the ACTH(4–10) sequence. Laboratory studies have examined neurotrophin-related gene expression and signaling in rodent tissues and models.

Identity before interpretation

Semax nomenclature can cover different chemical forms. Sequence, counter-ion, quantity, and lot-specific analytical results should be recorded rather than inferred from the short name.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

• BDNF, TrkB, and NGF-related expression in rodent brain and retinal tissues.
• Time-dependent transcriptional or protein changes in controlled neural model systems.
• The gap between mechanistic observations and claims about safety or outcomes.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

• A 2006 rat study measured hippocampal BDNF protein, BDNF transcripts, and TrkB-related changes after Semax exposure.
• A 2010 rat study reported time- and tissue-dependent NGF and BDNF gene-expression changes.
• These studies describe measured changes in specific models; they do not establish personal-use benefits or a safe route of administration.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

• Rodent gene-expression findings are not clinical evidence and should not be rewritten as consumer outcomes.
• FDA identifies immunogenicity and peptide-related impurity concerns for compounded drugs containing Semax.
• This Vespera item is a laboratory research material and is not an approved drug or compounded preparation.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

• Match sequence/form, SKU, nominal quantity, lot, method, and result.
• Record the species, tissue, time point, and assay when comparing a lot to published research.
• Do not use one purity value as a substitute for identity, quantity, microbial, endotoxin, or stability data.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

1. Dolotov et al. — Semax, BDNF, and TrkB expression in rat hippocampus (2006)Rodent molecular-signaling study.
2. Shadrina et al. — NGF and BDNF expression dynamics under Semax (2010)Rodent brain and retina gene-expression study.
3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded drugs containing Semax.